Diffuse Midline Glioma — Trials

Diffuse Midline Glioma — Trials · CancerIndex

Clinical trials

Registered studies

129 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 61
Recruiting: 32
Ph III recruiting: 1
Growth YoY: —
Industry share: 18%
Top sponsor: Nationwide Children's Hospital
Termination share: 43.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (23)

clinicaltrialsPublishedShowing 1–8 of 8 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03330197	A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG	terminated	Phase 1 / Phase 2	6	Alaunos TherapeuticsINDUSTRY	1	Aug 12, 2025	clinicaltrials
NCT03690869	REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma	terminated	Phase 1 / Phase 2	57	Regeneron PharmaceuticalsINDUSTRY	1	Apr 8, 2025